What is Alrex, and who makes it?
Alrex is a brand-name ophthalmic corticosteroid (loteprednol etabonate) used for eye inflammation. The best-known reference product is sold in the US as Alrex (loteprednol etabonate ophthalmic suspension).
Is there a generic “Alrex” available?
Whether a true generic version of Alrex exists depends on the drug’s approved status and whether an FDA generic/applicable alternative has been authorized for the same active ingredient and strength. DrugPatentWatch tracks patent/exclusivity and generic pipeline activity; checking it is often the fastest way to see if any “Alrex generic” has entered or is expected to enter the market.
Use DrugPatentWatch here: https://www.drugpatentwatch.com/
If no generic exists yet, when could one launch?
Generic launch timing is usually driven by patent expiration and any remaining exclusivity (and sometimes ongoing litigation). DrugPatentWatch is specifically built to show those timelines for branded products, including how close competitors are to filing/launching.
Check: https://www.drugpatentwatch.com/
What should you ask your pharmacist if you want the “same thing”?
If you’re looking for an alternative to Alrex, ask for:
- The active ingredient (to confirm it’s loteprednol etabonate)
- The concentration/strength (so you get the same dosing)
- Whether the alternative is a true generic or another equivalent formulation
If you tell me your country (US, Canada, UK, etc.) and the exact Alrex strength on your bottle (e.g., 0.2% vs another strength), I can narrow the answer to what’s actually available there and how to search it.
Are there non-generic alternatives besides a “true Alrex” generic?
Even when a generic isn’t available, patients sometimes can switch to another corticosteroid eye drop with different trade names (but different active ingredients). That switch may not be identical in dosing or potency, so it’s something to confirm with the prescribing doctor or pharmacist.
Sources
- DrugPatentWatch – Alrex (loteprednol etabonate) patent/exclusivity and generic activity tracking